NEW ORLEANS--(BUSINESS WIRE)--RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone. The in vitro study was presented yesterday in a science session during the 56th Annual Meeting of the Orthopaedic Research Society (ORS) by Matthew O’Donnell, Ph.D., R&D Manager for RepRegen.
